Belfeki N, Strazzulla A, Picque M, Diamantis S
Department of Internal Medicine, Groupe Hospitalier Sud Ile de France, Melun.
Reumatismo. 2020 Jan 28;71(4):199-202. doi: 10.4081/reumatismo.2019.1221.
Hyperferritinemia can be the result of inflammation, infection, iron overload, or other uncommon pathologies including hemophagocytic lymphohistiocytosis (HLH). The significance of its elevation and its association with poor prognosis and critical clinical situations is unclear. To study the spectrum of diagnosis associated with elevated serum ferritin, we made a retrospective review of patients admitted to our center from 2015 and 2017 with serum ferritin levels above 2000 μg L-1. The H score was retrospectively assessed in all cases to evaluate the possible presence of HLH. The degree of ferritinemia found was compared with the evaluation of the undelying diagnosis and the results of laboratory examinations. A total of 77 patients were identified with a serum ferritin level >2000 μg L-1. Hematological malignancy was the most prevalent diagnosis with n=20; severe infection was next with n=14. Eleven patients were diagnosed with HLH. The hemophagocytosis pictures on bone marrow smear and mortality rate were significantly correlated with ferritin level above 6000 μg L-1 (p<0.01). The comparison of the HLH subgroup with the rest of the cohort showed that fever, cytopenia (anemia, leucopenia, neutropenia and thrombocytopenia), hemophagocytosis pictures, and major liver disturbances were significantly increased in the HLH subgroup. The H score was significantly elevated in the subgroup of patients with ferritin above 6000 μg L-1, with a significatively higher probability of HLH (p<0.01). The mortality rate at 3 months was significantly increased in the HLH subgroup. Extreme hyperferritin cannot be considered as a specific marker for the diagnosis. The cut off of 6000 μg L-1 is significantly associated with HLH diagnosis. The H score is an interesting screening tool that physicians should use to rule out the probability of HLH when facing critical clinical situations.
高铁蛋白血症可能是炎症、感染、铁过载或其他罕见病症(包括噬血细胞性淋巴组织细胞增生症(HLH))的结果。其升高的意义及其与不良预后和危急临床情况的关联尚不清楚。为了研究与血清铁蛋白升高相关的诊断范围,我们对2015年至2017年入住我们中心且血清铁蛋白水平高于2000μg/L的患者进行了回顾性研究。对所有病例进行回顾性评估H评分,以评估HLH的可能存在情况。将所发现的铁蛋白血症程度与潜在诊断评估及实验室检查结果进行比较。共确定了77例血清铁蛋白水平>2000μg/L的患者。血液系统恶性肿瘤是最常见的诊断,有20例;严重感染次之,有14例。11例患者被诊断为HLH。骨髓涂片上的噬血细胞图像和死亡率与铁蛋白水平高于6000μg/L显著相关(p<0.01)。HLH亚组与其余队列的比较显示,HLH亚组的发热、血细胞减少(贫血、白细胞减少、中性粒细胞减少和血小板减少)、噬血细胞图像和严重肝脏功能障碍显著增加。铁蛋白高于6000μg/L的患者亚组中H评分显著升高,HLH的可能性显著更高(p<0.01)。HLH亚组3个月时的死亡率显著增加。极高的铁蛋白不能被视为诊断的特异性标志物。6000μg/L的临界值与HLH诊断显著相关。H评分是一种有趣的筛查工具,医生在面对危急临床情况时应使用它来排除HLH的可能性。